by Raynovich Rod | Jan 17, 2022 | 2020-21 Life Science Portfolios, 2023 Rayno Biopharmaceuticals Portfolio
1/22 …More Freefall on Friday Yesterday’s freefall action felt a lot like 2001 when the market was trying to digest the 1999 bubble days.As we have been saying for many months once the momentum slowed stay away from speculative stocks without financial...
by Raynovich Rod | Jul 26, 2021 | 2023 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Healthcare Stocks Are Tracking Well-Indices are at Record Highs Look to Large Cap Biopharma earnings in coming weeks. Pfizer on Wednesday. Momentum in speculative small caps are lagging so may need to wait for Q4. Macro concerns lie ahead: China, Infrastructure deal...
by Raynovich Rod | Feb 22, 2021 | 2020-21 Life Science Portfolios, Biopharmaceuticals
Update-2 2/25…Correction seems more real just after market indices hit new highs yesterday: QQQ down 3.49% piercing 200 MA at $312.83. An unusual down day when both bonds and stocks take a hit over concerns about rapidly rising 10 yr TSY rates now yielding...
by Raynovich Rod | Dec 21, 2020 | 2020-21 Life Science Portfolios, Biopharmaceuticals
Update-1 12/21…a good day despite flat indices with the XBI up 1.68% to $150, IBB flattish at $156. Momentum still favors small cap speculation. Gene therapy stocks are running hard but I own EDIT up 29% to $84 ! Other big movers are CRSP,NTLA and SGMO....
by Raynovich Rod | Dec 14, 2020 | 2020-21 Life Science Portfolios, 2023 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1. 12/15…With Biden being declared a winner the focus of macro turns to stimulus talks and the FED Meeting tomorrow. The market ebullience returned today with all major indices up over 1%. The Pfizer vaccine is rolling out with Moderna expected next. With...
by Raynovich Rod | Jan 21, 2020 | Biopharmaceuticals
Update-1 We remain on hold for taking on new positions. Biotech and healthcare stocks have made nice gains so let’s get through the earnings cycle. Markets are jittery despite rush to new highs at opening, S&P 500 down 0.82%, as of mid-day trading over...
by Raynovich Rod | Nov 30, 2019 | Biopharmaceuticals
Update-2 …12/3…Biotech among the leading sectors on a sell-off day With NASDAQ off 0.55% and the S&P down 0.68%, biotech stocks were oblivious to the trade worries and had a huge rally driven by gene therapy stocks. The XBI was up 1.47% and most mid...
by Raynovich Rod | Nov 24, 2019 | 2023 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 11/25/19… Rally right on track driven by NVS/MDCO deal, new product surge and cheap money from FED. As we said many time on this site XBI is the bellwether up 4.25% today (UP 13% in one month) as biotech stocks broke out last week. IBB up 2.46%. We...
by Raynovich Rod | Jun 30, 2019 | Biopharmaceuticals
Update-1 A bit of a sell-off in gene therapy but MGTX at new highs at $29.44. Profit taking on Sarepta down 3.84% to $150.59. Roche (RHHBY) and Merck (MRK) near new highs. Mid-caps mixed but Novacure (NVCR) rally 3.27% toward new highs. One of our top picks Amarin...
by Raynovich Rod | Mar 22, 2019 | Biopharmaceuticals
Update -2 March 24…Concerns about global growth, an inverted TSY yield curve and the German 10 year bond yield dropping below 10% triggered a major sell-off on Friday.The Russell 2000 dropped 3.62%. and the XBI dropped 4.62%. For the week ending 3/22: the XBI...